newsfilter
← Latest News
GlobeNewswire·

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Completed enrollment in the Phase 2b portion and